<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Wright Medical Group N.V.

    Wright Medical Group N.V.

    Wright Medical Group N.V. is a global medical device company focused on Extremitie...

    Wright Medical Group N.V. is a global medical d...

    Filing Type:    PU
    PDS Biotechnology Corporation

    PDS Biotechnology Corporation

    PDS Biotechnology has a growing pipeline of clinical-stage immunotherapies to trea...

    PDS Biotechnology has a growing pipeline of cli...

    Filing Type:    PU
    WINDCHIME HEALTH, INC.

    WINDCHIME HEALTH, INC.

    Windchime Health is here to help both patients and dentists. Their SaaS solution a...

    Windchime Health is here to help both patients ...

    Fundraising Status:    SD
    Filing Type:    CF
    Quotient Limited

    Quotient Limited

    We are an established, commercial-stage diagnostics company committed to reducing ...

    We are an established, commercial-stage diagnos...

    Filing Type:    PU
    Evelo Biosciences, Inc.

    Evelo Biosciences, Inc.

    Evelo Biosciences, Inc. is a clinical stage biotechnology company developing oral ...

    Evelo Biosciences, Inc. is a clinical stage bio...

    Filing Type:    PU
    Anthera Pharmaceuticals, Inc.

    Anthera Pharmaceuticals, Inc.

    Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focu...

    Anthera Pharmaceuticals, Inc., a development st...

    Amount Raised:    $65,500,000
    Fundraising Status:    VT
    Filing Type:    PU
    Cellectis S.A.

    Cellectis S.A.

    Cellectis is a clinical-stage biopharmaceutical company that harnesses the immune ...

    Cellectis is a clinical-stage biopharmaceutical...

    Filing Type:    PU
    Harpoon Therapeutics, Inc.

    Harpoon Therapeutics, Inc.

    Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel ...

    Harpoon Therapeutics is a clinical-stage immuno...

    Filing Type:    PU
    Neoleukin Therapeutics, Inc.

    Neoleukin Therapeutics, Inc.

    Neoleukin is a biopharmaceutical company creating next generation immunotherapies ...

    Neoleukin is a biopharmaceutical company creati...

    Filing Type:    PU
    iCAD inc.

    iCAD inc.

    iCAD, Inc. an industry-leading provider of advanced image analysis, workflow solut...

    iCAD, Inc. an industry-leading provider of adva...

    Filing Type:    PU
    Advaxis, Inc.

    Advaxis, Inc.

    Advaxis was founded on the vision that no one should suffer from the burdens of ca...

    Advaxis was founded on the vision that no one s...

    Filing Type:    PU
    CytomX Therapeutics, Inc.

    CytomX Therapeutics, Inc.

    CytomX Therapeutics develops Probody™ therapeutics for the treatment of cancer. ...

    CytomX Therapeutics develops Probody™ therape...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.